Question explored with the scientific record
Is an immunosuppressant shot worth it for a AS?
The short version: for active ankylosing spondylitis, an injected biologic has real trial evidence of symptom relief, but every trial here is short, and the serious infections are real.
Whether it is "worth it" depends on how active your disease is and what you have already tried. The strongest evidence is for injected TNF blockers. In a randomized, placebo-controlled trial of golimumab, about 59 to 60 in 100 patients hit the main improvement measure at 14 weeks versus about 22 in 100 on placebo [4]. That is a genuine, controlled benefit, not a lab-value surrogate. But that trial ran only 24 weeks, and it was funded and analyzed with the manufacturer's involvement [4]. Longer-term safety was not assessed [4].
The costs are not hypothetical. Infections were more common on the drug (about 46 to 49 in 100 versus 36 in 100 on placebo) [4]. Case reports describe a life-threatening thigh abscess after infliximab [3] and brain abscesses during etanercept therapy [1]. A large claims analysis found biologics linked to fewer complications but far higher cost [2]. A newer oral drug, upadacitinib, held 71 in 100 patients at 52 weeks with no serious infections in a small single-center group of 45 [5], but that is uncontrolled and small.
| Group | Main response (week 14) | Infections (week 24) |
|---|---|---|
| Golimumab 50 mg | 59.4% [4] | 46.4% [4] |
| Golimumab 100 mg | 60.0% [4] | 48.6% [4] |
| Placebo | 21.8% [4] | 36.4% [4] |
What this retrieval cannot see: head-to-head trials against physical therapy or NSAIDs alone, and any long-term cancer or infection data. Those gaps are the search's limit, not proof they don't exist.
My call: worth trying if your disease is active and NSAIDs have failed, with eyes open about infection risk. Confidence: moderate.
Sources used 5
-
Brain Abscesses Complicating Acute Pneumococcal Meningitis During Etanercept Therapy
A 61-year-old man on etanercept therapy for ankylosing spondylitis developed multiple brain abscesses as a rare complication of community-acquired pneumococcal meningitis, likely due to immunosuppression from etanercept; despite initial deterioration, targeted antibiotic therapy…
DOI: 10.3121/cmr.2012.1049 -
Treatment patterns, complications, and direct medical costs associated with ankylosing spondylitis in Chinese urban patients: a retrospective claims dataset analysis
A retrospective cross-sectional analysis of the 2013 China Health Insurance Research Association (CHIRA) urban claims database describing treatment patterns, complications, and direct medical costs for ankylosing spondylitis (AS) in Chinese urban patients, finding biologics are …
DOI: 10.1080/13696998.2016.1227829 -
A Life-Threatening Abscess in a Patient Treated with a Tumour Necrosis Factor-Alpha Antagonist: A Case Report
This case report describes a 25-year-old man with ankylosing spondylitis who developed a life-threatening abscess in the left thigh after treatment with the TNF-α antagonist infliximab, highlighting the risks of severe infections associated with immunosuppressive therapies.
DOI: 10.1177/230949900901700223 -
Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double‐blind, placebo‐controlled, phase III trial
In a large, multicenter randomized trial (GO-RAISE), golimumab at 50 mg or 100 mg given subcutaneously every 4 weeks significantly improved ASAS20 responses and quality of life versus placebo through 24 weeks in patients with active ankylosing spondylitis, with a safety profile …
DOI: 10.1002/art.23969 -
Real-World Effectiveness and Safety of Upadacitinib in Tumor Necrosis FactorInhibitor Refractory Axial Spondyloarthritis: 52-Week Outcomes from a Single-Center Cohort
In a single-center retrospective cohort of 45 Turkish axial spondyloarthritis patients who failed TNFi, upadacitinib 15 mg once daily was associated with sustained clinical improvements, 71.1% 52-week drug retention, and no serious infections or thromboembolic events.
DOI: 10.5152/archrheumatol.2025.11098